Our expertise consist on the use of the same tools as the pharma industry does to find new drugs in molecular databases (i.e., virtual screening with protein-ligand docking, pharmacophores, electrostatic/shape comparisons) but applying them to databases of natural products (and therefore likely to be incorporated as bioactive ingredients, eg for functional food). Since the COVID-19 pandemic, work is underway on the development of antivirals for SARS-CoV-2 (M-pro inhibitors, among others) and on the analysis of virus mutations.
